350 related articles for article (PubMed ID: 34201614)
1. Monosomy 3 Is Linked to Resistance to MEK Inhibitors in Uveal Melanoma.
Mergener S; Siveke JT; Peña-Llopis S
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201614
[TBL] [Abstract][Full Text] [Related]
2. Chromosome 3 status combined with BAP1 and EIF1AX mutation profiles are associated with metastasis in uveal melanoma.
Ewens KG; Kanetsky PA; Richards-Yutz J; Purrazzella J; Shields CL; Ganguly T; Ganguly A
Invest Ophthalmol Vis Sci; 2014 Jun; 55(8):5160-7. PubMed ID: 24970262
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of chromosomal imbalances, gene mutations, and BAP1 expression in uveal melanoma.
Patrone S; Maric I; Rutigliani M; Lanza F; Puntoni M; Banelli B; Rancati S; Angelini G; Amaro A; Ligorio P; Defferrari C; Castagnetta M; Bandelloni R; Mosci C; DeCensi A; Romani M; Pfeffer U; Viaggi S; Coviello DA
Genes Chromosomes Cancer; 2018 Aug; 57(8):387-400. PubMed ID: 29689622
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Germline versus Somatic BAP1 Mutations for Risk of Metastasis in Uveal Melanoma.
Ewens KG; Lalonde E; Richards-Yutz J; Shields CL; Ganguly A
BMC Cancer; 2018 Nov; 18(1):1172. PubMed ID: 30477459
[TBL] [Abstract][Full Text] [Related]
5. Comparing the Prognostic Value of BAP1 Mutation Pattern, Chromosome 3 Status, and BAP1 Immunohistochemistry in Uveal Melanoma.
van de Nes JA; Nelles J; Kreis S; Metz CH; Hager T; Lohmann DR; Zeschnigk M
Am J Surg Pathol; 2016 Jun; 40(6):796-805. PubMed ID: 27015033
[TBL] [Abstract][Full Text] [Related]
6. The Potential Role of Selected miRNA in Uveal Melanoma Primary Tumors as Early Biomarkers of Disease Progression.
Wróblewska JP; Lach MS; Ustaszewski A; Kulcenty K; Ibbs M; Jagiełło I; Suchorska WM; Marszałek A
Genes (Basel); 2020 Mar; 11(3):. PubMed ID: 32131485
[TBL] [Abstract][Full Text] [Related]
7. Prognostic parameters in uveal melanoma and their association with BAP1 expression.
van Essen TH; van Pelt SI; Versluis M; Bronkhorst IH; van Duinen SG; Marinkovic M; Kroes WG; Ruivenkamp CA; Shukla S; de Klein A; Kiliç E; Harbour JW; Luyten GP; van der Velden PA; Verdijk RM; Jager MJ
Br J Ophthalmol; 2014 Dec; 98(12):1738-43. PubMed ID: 25147369
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of chromosomal aberrations and GNAQ, GNA11 and BAP1 mutations in uveal melanoma.
Staby KM; Gravdal K; Mørk SJ; Heegaard S; Vintermyr OK; Krohn J
Acta Ophthalmol; 2018 Feb; 96(1):31-38. PubMed ID: 28444874
[TBL] [Abstract][Full Text] [Related]
9. Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma.
Cheng H; Chua V; Liao C; Purwin TJ; Terai M; Kageyama K; Davies MA; Sato T; Aplin AE
Mol Cancer Ther; 2017 Mar; 16(3):516-528. PubMed ID: 28138035
[TBL] [Abstract][Full Text] [Related]
10. Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma.
Robertson AG; Shih J; Yau C; Gibb EA; Oba J; Mungall KL; Hess JM; Uzunangelov V; Walter V; Danilova L; Lichtenberg TM; Kucherlapati M; Kimes PK; Tang M; Penson A; Babur O; Akbani R; Bristow CA; Hoadley KA; Iype L; Chang MT; ; Cherniack AD; Benz C; Mills GB; Verhaak RGW; Griewank KG; Felau I; Zenklusen JC; Gershenwald JE; Schoenfield L; Lazar AJ; Abdel-Rahman MH; Roman-Roman S; Stern MH; Cebulla CM; Williams MD; Jager MJ; Coupland SE; Esmaeli B; Kandoth C; Woodman SE
Cancer Cell; 2017 Aug; 32(2):204-220.e15. PubMed ID: 28810145
[TBL] [Abstract][Full Text] [Related]
11. Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner.
Khalili JS; Yu X; Wang J; Hayes BC; Davies MA; Lizee G; Esmaeli B; Woodman SE
Clin Cancer Res; 2012 Aug; 18(16):4345-55. PubMed ID: 22733540
[TBL] [Abstract][Full Text] [Related]
12. Targeting the YAP/TAZ Pathway in Uveal and Conjunctival Melanoma With Verteporfin.
Brouwer NJ; Konstantinou EK; Gragoudas ES; Marinkovic M; Luyten GPM; Kim IK; Jager MJ; Vavvas DG
Invest Ophthalmol Vis Sci; 2021 Apr; 62(4):3. PubMed ID: 33798262
[TBL] [Abstract][Full Text] [Related]
13. HDAC Inhibition Enhances the
Faião-Flores F; Emmons MF; Durante MA; Kinose F; Saha B; Fang B; Koomen JM; Chellappan SP; Maria-Engler SS; Rix U; Licht JD; Harbour JW; Smalley KSM
Clin Cancer Res; 2019 Sep; 25(18):5686-5701. PubMed ID: 31227503
[TBL] [Abstract][Full Text] [Related]
14. The AMP-dependent kinase pathway is upregulated in BAP1 mutant uveal melanoma.
Chua V; Han A; Bechtel N; Purwin TJ; Hunter E; Liao C; Harbour JW; Aplin AE
Pigment Cell Melanoma Res; 2022 Jan; 35(1):78-87. PubMed ID: 34347929
[TBL] [Abstract][Full Text] [Related]
15. Metabolic Adaptations to MEK and CDK4/6 Cotargeting in Uveal Melanoma.
Teh JLF; Purwin TJ; Han A; Chua V; Patel P; Baqai U; Liao C; Bechtel N; Sato T; Davies MA; Aguirre-Ghiso J; Aplin AE
Mol Cancer Ther; 2020 Aug; 19(8):1719-1726. PubMed ID: 32430489
[TBL] [Abstract][Full Text] [Related]
16. BAP1 mutant uveal melanoma is stratified by metabolic phenotypes with distinct vulnerability to metabolic inhibitors.
Han A; Purwin TJ; Bechtel N; Liao C; Chua V; Seifert E; Sato T; Schug ZT; Speicher DW; Harbour JW; Aplin AE
Oncogene; 2021 Jan; 40(3):618-632. PubMed ID: 33208912
[TBL] [Abstract][Full Text] [Related]
17. Transposase mapping identifies the genomic targets of BAP1 in uveal melanoma.
Yen M; Qi Z; Chen X; Cooper JA; Mitra RD; Onken MD
BMC Med Genomics; 2018 Nov; 11(1):97. PubMed ID: 30400891
[TBL] [Abstract][Full Text] [Related]
18. Bioinformatics analysis of GNAQ, GNA11, BAP1, SF3B1,SRSF2, EIF1AX, PLCB4, and CYSLTR2 genes and their role in the pathogenesis of Uveal Melanoma.
Akin-Bali DF
Ophthalmic Genet; 2021 Dec; 42(6):732-743. PubMed ID: 34353217
[TBL] [Abstract][Full Text] [Related]
19. Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers.
Abdel-Rahman MH; Pilarski R; Cebulla CM; Massengill JB; Christopher BN; Boru G; Hovland P; Davidorf FH
J Med Genet; 2011 Dec; 48(12):856-9. PubMed ID: 21941004
[TBL] [Abstract][Full Text] [Related]
20. BAP1 Loss Is Associated with DNA Methylomic Repatterning in Highly Aggressive Class 2 Uveal Melanomas.
Field MG; Kuznetsov JN; Bussies PL; Cai LZ; Alawa KA; Decatur CL; Kurtenbach S; Harbour JW
Clin Cancer Res; 2019 Sep; 25(18):5663-5673. PubMed ID: 31285370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
